Author:
Yi Yingping,Li Yawei,Hou Anran,Ge Yanqiu,Xu Yuan,Xiong Gang,Yang Xinlei,Acevedo Stephanie Ann,Shi Lizheng,Xu Hua
Funder
General Project Jiangxi Provincial Science and Technology Department
Scientific and Technological Innovation Platform of Jiangxi Provincial Science and Technology Department
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference41 articles.
1. World Health Organization. Global report on diabetes. Geneva: WHO; 2016.
2. Valentine V, Goldman J, Shubrook JH. Rationale for initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes. Diabetes Ther. 2017;8:739–52.
3. Yu CG, Fu Y, Fang Y, Zhang N, Sun RX, Zhao D, Zhang BY, et al. Fighting type-2 diabetes: present and future perspectives. Curr Med Chem. 2017;24:1–17.
4. Xiong Z, Yuan L, Guo X, Lou Q, Zhao F, Shen L, Sun Z, et al. Rejection of insulin therapy among patients with type 2 diabetes in China: reasons and recommendations. Chin Med J. 2014;127:3530–6.
5. Wong J, Tabet E. The introduction of insulin in type 2 diabetes mellitus. Aust Fam Physician. 2015;44:278–83.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献